De-risking lentiviral vector production using a robust, scalable, suspension-based platform
Sponsor
Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.
Lentiviral vectors (LV) are a potent tool in the growing field of cell and gene therapy because they enable efficient delivery of genetic material into cells for therapies such as CAR-T and HSC-based gene therapies. With the increasing number of clinical applications and interest in the field, robust, scalable, and cost-effective platforms for GMP manufacturing of high-quality lentiviral vectors are urgently needed.
Many companies looking to utilize lentiviral vectors have faced the common roadblocks and problems associated with traditional LV production of undesirable regulatory elements of plasmids, high costs, and long lead times for manufacturing slots.
In this webinar, we will describe ElevateBio BaseCamp’s LentiPeak™ LV production platform - a robust and well-established platform process for LV production based on transient transfection of serum-free cells grown in suspension, which is designed to address common industry problems.
The LentiPeak™ platform has displayed high upstream infectious titers (~1E8 TU/mL) and a low particle-to-infectious titer ratio (< 1000 particles/TU) across a variety of commonly utilized therapeutic transgenes, and has demonstrated robust scalability in both small-scale and large-scale bioreactors. The final purified product from LentiPeak™ shows efficient and potent transduction of primary cells and remarkable reduction in the host cell protein (HCP), host cell DNA, and plasmid DNA impurity content.
While aiming to generate a robust, scalable and GMP-compatible process, BaseCamp also focused on streamlining workflows to accelerate our partner’s timelines by immediate access to manufacturing slots and a seamless transition from PD to GMP manufacturing in the following aspects: ability to produce LVs coding for different genes of interest (GOI) including CAR/TCR constructs, employment of the single-use technologies, employment of non-animal-derived raw materials, and alignment of equipment, protocols, and data collection tools between PD labs and GMP manufacturing suites.
- A review of current industry-wide challenges faced by companies utilizing lentivirus as therapeutic modality
- Overview of the development of the LentiPeak™ platform: from upstream titer optimization to downstream impurity reduction and considerations for cGMP-compatible production
- A review of the benefits of utilizing a lentivirus production platform: time savings, scalability, accessibility to manufacturing slots
SPEAKERS